| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2006 | WO2006004622A3 Inhibition of bid-induced cell-death using small organic molecules |
| 07/13/2006 | WO2006002088A3 Amino-quinazoline derivatives as antitumor agents |
| 07/13/2006 | WO2005123087A3 C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
| 07/13/2006 | WO2005120475A3 Pharmaceutical composition for the treatment of bacterial infections and sepsis |
| 07/13/2006 | WO2005117910A3 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
| 07/13/2006 | WO2005115397A3 Compositions and treatments for modulating kinase and/or hmg-coa reductase |
| 07/13/2006 | WO2005113012A3 Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass |
| 07/13/2006 | WO2005112945A3 Synthesis of tetracyclines and analogues thereof |
| 07/13/2006 | WO2005112635A3 Uridine effects on dopamine release |
| 07/13/2006 | WO2005110478A3 Combination therapy for treating fibrotic disorders |
| 07/13/2006 | WO2005110413A3 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 07/13/2006 | WO2005110364A3 Drug delivery systems and methods for treatment of an eye |
| 07/13/2006 | WO2005109001A3 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| 07/13/2006 | WO2005108573A3 Method to induce rnai in prokaryotic organisms |
| 07/13/2006 | WO2005107735A3 Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a |
| 07/13/2006 | WO2005102330A3 Amino methylated 2-pyridinones |
| 07/13/2006 | WO2005102288A3 Lozenge for delivery of dextromethorphan |
| 07/13/2006 | WO2005094278A3 N-acylated chitinous polymers and methods of use thereof |
| 07/13/2006 | WO2005084710A3 Nanocell drug delivery system |
| 07/13/2006 | WO2005082006A3 Method for providing antimicrobial composite yarns, composite fabrics and articles made therefrom |
| 07/13/2006 | WO2005077416A3 Lipid rafts and clostridial toxins |
| 07/13/2006 | WO2005074990A3 Methods of preventing and treating sars using low ph respiratory tract compositions |
| 07/13/2006 | WO2005037213A3 Antiinflammatory inhibitors of respiratory burst in adherent neutrophils |
| 07/13/2006 | WO2004096139A3 Aza spiro alkane derivatives as inhibitors of metalloproteases |
| 07/13/2006 | WO2004010842A3 Lipophilic electrophoretic probes |
| 07/13/2006 | WO2003095621A3 Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferactive disorder |
| 07/13/2006 | US20060155129 etherification of 4-(6'-chloro-5'-methylpyrimidin-4'-yloxypiperidine)-1-carboxylic acid isopropyl ester with 2-Fluoro-4-methanesulfonylphenol, to form 4-[6-(2-fluoro-4-methanesulfonyl-phenoxy)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic Acid Isopropyl Ester; antidiabetic agents |
| 07/13/2006 | US20060155128 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| 07/13/2006 | US20060155111 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 07/13/2006 | US20060154993 Method for treating and preventing male infertility |
| 07/13/2006 | US20060154992 Enantiomers of O-desmethyl venlafaxine |
| 07/13/2006 | US20060154991 administering 1-(5-methyl-2-propan-2-ylcyclohexyl)oxy-3-piperidin-1-ylpropan-2-ol, for the treatment fungal infection in humans and mammals; inhibitors of the budded-to-hyphal transition of yeasts |
| 07/13/2006 | US20060154990 Use of MEK inhibitors in treating abnormal cell growth |
| 07/13/2006 | US20060154989 For use as contrast media; x-ray diagnosis and magnetic resonance imaging |
| 07/13/2006 | US20060154988 intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, |
| 07/13/2006 | US20060154987 Method for the preparation of crystalline dexloxiglumide and products obtained |
| 07/13/2006 | US20060154986 A triacylglyceride to deliver health promoting fatty acids to the upper gastrointestinal tract and skin |
| 07/13/2006 | US20060154985 For therapy of prostate cancer |
| 07/13/2006 | US20060154984 Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof |
| 07/13/2006 | US20060154983 Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions |
| 07/13/2006 | US20060154982 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases such as cancer, psoriasis, arteriosclerosis or is at risk of restenosis of the coronary arteries after vascular surgery |
| 07/13/2006 | US20060154981 Method of reducing intraocular pressure and treating glaucoma |
| 07/13/2006 | US20060154980 Improved cox-2 inhibitory compositions and therapeutic regimen |
| 07/13/2006 | US20060154979 Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity |
| 07/13/2006 | US20060154977 Therapeutic molecules and methods-1 |
| 07/13/2006 | US20060154976 Reducing the incidence of fibrosis by the co-administration of effective amounts of telmisartan and ramipril; strokes; cardiovascular disorders; organoprotective, tissue-protective, and vasculoprotective effects of combined treatment |
| 07/13/2006 | US20060154975 Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof |
| 07/13/2006 | US20060154974 N-thiazol-2-yl-benzamide derivatives |
| 07/13/2006 | US20060154973 Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof |
| 07/13/2006 | US20060154972 Amino acids with affinity for the alpha-2-delta-protein |
| 07/13/2006 | US20060154971 Combination therapies of cicletanine and lacidipine |
| 07/13/2006 | US20060154970 Alanines compounds, method of preparing them and their use |
| 07/13/2006 | US20060154969 Adenosine receptor selective modulators |
| 07/13/2006 | US20060154968 Treating neurological disorders using selective antagonists of persistent sodium current |
| 07/13/2006 | US20060154966 Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
| 07/13/2006 | US20060154965 N-(6-Benzenesulfonyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-N'-methyl-ethane-1,2-diamine, and indane analogs; modulating both 5-HT6 and 5-HT2A receptors; selective serotoninreceptor antagonists; central nervous system; Parkinson's disease; antidepressants; eating/sleeping disorders; drug abuse; headaches |
| 07/13/2006 | US20060154964 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/13/2006 | US20060154963 Phosphatase and Tensin homolog deleted on chromosome Ten (PTEN), a tumor suppressor gene or calcium sensitive potassium channel modulators, comprising tetrazolylalkoxy-dihydrocarbostyril compounds such as Cilostazol , used for the treatment of Alzheimer's disease |
| 07/13/2006 | US20060154962 Obesity, diabetes, inflammatory and immune diseases |
| 07/13/2006 | US20060154961 Thiadiazole compounds and methods of use |
| 07/13/2006 | US20060154960 Phosphodiesterase 4 inhibitors |
| 07/13/2006 | US20060154959 Increased prostacyclin activity; oral formulations; diabetes, diabetic complications, dyslipidemia, and metabolic disorders |
| 07/13/2006 | US20060154958 Bicyclic heterocycles as cannabinoid receptor modulators |
| 07/13/2006 | US20060154957 Crystalline clopidogrel hydrobromide and processes for preparation thereof |
| 07/13/2006 | US20060154956 N-(1-Benzyl-2-oxo-1,2,3,4-tetrahydro-1,6-naphthyridin-3-yl)-benzenesulfonamide; CB-1 antagonist; regulating appetitive behavior |
| 07/13/2006 | US20060154955 Bicyclic heterocycles as cannabinoid receptor modulators |
| 07/13/2006 | US20060154954 Combinations and use of selected pharmaceutically active compounds |
| 07/13/2006 | US20060154953 Amorphous tacrolimus and preparation thereof |
| 07/13/2006 | US20060154952 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation-and ummunologically-mediated diseases |
| 07/13/2006 | US20060154951 Quaternary antimuscarinic compounds for the treatment of bladder diseases |
| 07/13/2006 | US20060154950 Novel Use of rapamycin and structural analogues thereof |
| 07/13/2006 | US20060154949 Arylindenopyridines and related therapeutic and prophylactic methods |
| 07/13/2006 | US20060154948 Treating allergic and inflammatory conditions |
| 07/13/2006 | US20060154947 Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments |
| 07/13/2006 | US20060154946 Method for treating eating disorders by selective extinction with transdermal naloxone |
| 07/13/2006 | US20060154945 e.g. (R)-3'-(5-phenyl-thiophen-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one; nicotinic acetylcholine receptor agonist; antidepressant, neurodegenerative diseses; Alzheimer's disease, cognitive or attention disorders, smoking cessation, schizophrenia, analgesia |
| 07/13/2006 | US20060154944 N-(3,5-dimethylphenyl)-1-(3-fluorophenyl)-1,9-dihydrospiro[ beta-carboline-4,1'-cyclopropane]-2(3H)-carboxamide;affinity for mitochondrial benzodiazepine receptors preventive/therapeutic to stress-related diseases; irritable bowel syndrome; anxiolytic agents; nervous/respiratory system disorders;asthma |
| 07/13/2006 | US20060154943 Trimethoprim derivative; 5-[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine; potent activity against dihydrofolate reductase, mutated enzyme; superior bioavailability, antibacterial activity; gram positive and negative pathogens |
| 07/13/2006 | US20060154942 Quinazolinone derivatives useful as anti-hyperalgesic agents |
| 07/13/2006 | US20060154941 Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| 07/13/2006 | US20060154940 Reacting 4-Chloro-1-(2-fluoro-4-methanesulfonyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidine with 4-hydroxy-piperidine-1-carboxylic acid isopropyl ester in presence of triphenylphosphine and Diisopropyl azodicarboxylate; modulators of glucose metabolism, therapy of metabolic disorder, diabetes and obesity |
| 07/13/2006 | US20060154939 Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| 07/13/2006 | US20060154938 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| 07/13/2006 | US20060154937 Novel farnesyl protein transferase inhibitors and their use to treat cancer |
| 07/13/2006 | US20060154936 Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| 07/13/2006 | US20060154935 Quinazolines useful as modulators of ion channels |
| 07/13/2006 | US20060154934 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 07/13/2006 | US20060154933 Inhibitors of Cdc25 phosphatases |
| 07/13/2006 | US20060154932 Pharmaceutical compositions and method of treating parkinson's disease |
| 07/13/2006 | US20060154931 phosphodiesterase (PDE) inhibitors; 2-[4-(4-Pyridin-4-yl-2H-pyrazol-3-yl)-phenoxymethyl]-quinoline; for treating central nervous system disorders, neurodegenerative and psychiatric disorders |
| 07/13/2006 | US20060154930 Substituted amino heterocycles as vr-1 antagonists for treating pain |
| 07/13/2006 | US20060154929 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds |
| 07/13/2006 | US20060154928 Novel 2,4-diamino-1,3,5-triazine derivative |
| 07/13/2006 | US20060154926 Methods of treating alzheimer's disease using aryl alkanoic acid amides |
| 07/13/2006 | US20060154925 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 07/13/2006 | US20060154922 Muscarinic agonists |
| 07/13/2006 | US20060154921 administering calcitonin gene-related peptide (CGRP) antagonists such as 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-1-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butane-1,4-dione |
| 07/13/2006 | US20060154920 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents |
| 07/13/2006 | US20060154919 Combination of a glycine transporter (GLYT1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| 07/13/2006 | US20060154918 Injectable nanoparticulate olanzapine formulations |